Johnson & Johnson's Prospects in 2014

Johnson & Johnson had a strong year in 2013, but what about 2014? A rival bio-similar from Hospira threatens its largest drug by sales, Remicade. In addition, a weak medical device market has already been discussed by a company like General Electric. So, where next for Johnson & Johnson?

Jan 26, 2014 at 6:45PM

The recent earnings results from Johnson & Johnson (NYSE:JNJ) were met with a near 2% sell-off on the day. As ever, a lot of journalists and commentators immediately searched for a negative in the results or guidance in order to justify the drop. There was nothing significantly wrong with the results. However, the company's stock looks fairly valued and it probably needs to surprise the investment community on the upside in order to move significantly higher in 2014.

The running story with its divisions in 2013 was one of strong pharmaceutical sales, weakening medical device & diagnostics, and moderately growing consumer products. The fourth quarter results stuck to the script, and it's hard to see how things will change much in 2014.

Pharmaceuticals (39.4% of 2013 sales)
Johnson & Johnson's pharmaceutical performance stood out because it had a number of new drugs in early marketing stages, while continuing to generate strong growth with its Remicade (rheumatoid arthritis) treatment.

Remicade sales grew by nearly 14% in the fourth quarter, and generated more than 23% of pharmaceutical sales and over 9% of total company sales in the quarter. Meanwhile, some of its newer drugs achieved very strong growth:

Drug Treatment Forth Quarter Sales ($m) Fourth Quarter Growth
Stelara psoriais 417 55%
Simponi rheumatoid arthritis 254 40%
Invega Sustenna anti-psychotic 350 54%
Xarelto anti-coagulant 271 n/a
Zytiga castration-resistant prostate cancer 495 87.5%

Source: Company Presentations

Together, these fast-growing drugs generated 24.4% of total pharmaceutical sales in the fourth quarter. Growth should continue at a strong pace in 2014 as the company's sales reach is expanded.

However, one potential problem could be Hospira's (NYSE:HSP) biosimilar for Remicade, called Inflectra. Hospira's drug was approved by the European Commission in late 2013, and has proved to be comparable to Remicade in a large-scale trial.   Johnson & Johnson's patent protection for Remicade will run out in most countries in Europe in February 2015, and in February 2018 in the United States. Given the importance of Remicade, Hospira's Inflectra could turn out to be a challenge to Johnson & Johnson in future.

Medical Device & Diagnostics (40% of 2013 sales)
Pharmaceuticals did well, but the medical device & diagnostics division is facing another difficult year. The whole indusrtry has found it tough. Medical device sales are not often seen as economically sensitive, but when the economy is slow patients tend to make fewer visits to the physician. Ultimately, this results in fewer surgical procedures. Throw in a climate of austerity in hospital spending, and the outlook for medical devices looks moderate in mature markets. Indeed, Johnson & Johnson's management outlined on the conference call that surgical lab procedures were "flat over the last 12 months" in the United States.

Consumer Products (20.6% of 2013 sales)
The 2.8% increase in consumer products sales for the fourth quarter was disappointing to some, but Foolish investors should note four things about the division.

First, the consumer products division is probably the most visible of its operations, though it's actually the least important in terms of sales. Second, it's also the division with the largest reliance on international markets, and currency effects reduced sales by a significant amount. In fact, on a constant currency basis, consumer products sales were up 4.4% in the fourth quarter.  Third, the company achieved its aim of getting 75% of its over-the-counter brands (previously affected by production problems) back onto the shelves. Indeed, its U.S. OTC sales rose 21.6% in the fourth quarter. Finally, if you exclude the effects of the sales of the manual toothbrush (oral care) and women's sanitary protection (women's health) businesses then U.S. sales were actually up 10%, with global operational sales growth up 6%. 

Johnson & Johnson in 2014
Looking into 2014, investors should focus on three things:

  • Acceleration in the economic recovery so medical device sales can pick up inline with an increase in surgical procedures.
  • Ongoing development of pharmaceutical sales, and activity to protect future market share for Remicade in Europe.
  • An improvement in its international consumer products sales, as they only grew 3.1% operationally in 2013.

Achieving two of the three things should provide for some upside surprise, and Johnson & Johnson needs it. On current analyst estimates, it trades on a valuation of 16 times forward earnings. The company also has only 6% and 7.4% earnings-per-share growth estimated in the next two years. This makes it look like a fairly valued stock.

Three Dow dividend stocks investors need
If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.

Lee Samaha has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of General Electric Company and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers